{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:25Z","timestamp":1791521425232,"version":"4.3.4"},"reference-count":3,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2026.2014160","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:20Z","timestamp":1791519980000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: B-cell engineering in malignant and non-malignant disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Lucia","family":"Sereni","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Pediatric Oncology","place":["Boston, MA, United States"]},{"name":"Boston Children\u2019s Hospital, Hematology\/Oncology Division","place":["Boston, MA, United States"]},{"name":"Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Capo","sequence":"additional","affiliation":[{"name":"San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]},{"name":"Milan Unit, Institute of Genetic and Biomedical Research, Consiglio Nazionale delle Ricerche","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pala","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases (NIH)","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.09.019","article-title":"Genome edited B cells: a new frontier in immune cell therapies","volume":"29","author":"Rogers","year":"2021","journal-title":"Mol Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02757-y","article-title":"Engineering B cells to treat and study human disease","volume":"43","author":"Trivedi","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.adz8994","article-title":"B lymphocyte protein factories produced by hematopoietic stem cell gene editing","volume":"392","author":"Hartweger","year":"2026","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.2014160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:21Z","timestamp":1791519981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.2014160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":3,"alternative-id":["10.3389\/fimmu.2026.2014160"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.2014160","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"2014160"}}